Investor Presentaiton

Abbreviations AA Alopecia Areata EoE Eosinophilic Esophagitis MTD Maximum Tolerated Dose RP3D Recommended Phase 3 Dose American Association for Cancer AACR ESA Erythropoietin Stimulating Agents MZL Marginal Zone Lymphoma ROS C-ROS Oncogene Research Adj Adjuvant ESCC Esophageal Squamous Cell Carcinoma nHCM Non-Obstructive Hypertrophic Cardiomyopathy RR Relapsed Refractory AE Adverse Event FDC Fixed Dose Combination ND Newly Diagnosed SAE Serious Adverse Event AHA American Heart Association FDA Food & Drug Administration NSCLC Non-Small Cell Lung Cancer SC Subcutaneous AML Acute Myeloid Leukemia FL Follicular Lymphoma NTD Non-Transfusion Dependent SCT Stem Cell Transplant ASH American Society of Hematology Hb Hemoglobin NTRK Neurotrophic Tyrosine Receptor Kinase SLE Systemic Lupus Erythematosus BCMA B-Cell Maturation Antigen HCC Hepatocellular Carcinoma NYHA New York Health Association SoC Standard of Care BID Twice a Day HFPEF Heart Failure w/ Preserved Ejection Fraction OHCM Obstructive Hypertrophic Cardiomyopathy SPGA Static Physicians Global Assessment BIW Twice a week iNHL Indolent Non-Hodgkin's Lymphoma ORR Overall Response Rate SRI Systemic Lupus Responder Index CAR T Chimeric Antigen Receptor Therapy 1-0 Immuno-Oncology OS Overall Survival SRT Septal Reduction Therapy CCRT CD Concurrent Chemoradiation Therapy Crohn's Disease IPSS-R IV International Prognostic Scoring System Intravenous PASI Psoriasis Area and Severity Index SSP Secondary Stroke Prevention PCR Pathological Complete Response SubQ/SC Subcutaneous CDAI Crohn's Disease Activity Index LBCL Large B-Cell Lymphoma PDCT Platinum-Based Chemotherapy TD Transfusion Dependent CLL CM Chronic Lymphocytic Leukemia Checkmate LVOT Left Ventricular Outflow Tract PDL Programmed Death Ligand TE Transplant Eligible mCRPC Metastatic Castration-Resistant Prostate Cancer PDUFA Prescription Drug User Fee Act TEAE Treatment Emergent Adverse Events CR Complete Response MDS Myelodysplastic Syndrome PF Pulmonary Fibrosis TKI Tyrone Kinase Inhibitor CRR Complete Remission Rate CRC Colorectal Cancer Mel mDSD modified Daily Symptom Diary Melanoma PFS Progression Free Survival TRAE POC Proof of Concept TE Treatment Related Adverse Events Transplant Eligible DFS Disease-free survival MF Myelofibrosis PsA Psoriatic Arthritis TNF Tumor Necrosis Factor DLBCL Diffuse Large B-Cell Lymphoma MIUC Muscle Invasive Urothelial Cancer PsO Psoriasis UC Ulcerative Colitis DLE Discoid Lupus Erythematosus MM Multiple Myeloma QD Once Daily VO2 Volume of Oxygen DLT Dose Limiting Toxicity MR EADV European Academy of Dermatology and Venereology MS Minimal Response Multiple Sclerosis QW Once Weekly RBC-TI Red Blood Cell Transfusion Independence EASI Eczema Area & Severity Index MSI-H High Microsatellite Instability RCC Renal Cell Carcinoma EFS Event Free Survival MSS Microsatellite Stable RFS Recurrence-free survival ll Bristol Myers Squibb™ | Q3 2023 Results RP2D Recommended Phase 2 Dose Not for Product Promotional Use 56

View entire presentation